Eric Faulkner, RTI Health Solutions Director of US Market Access and Reimbursement, will speak at the Phacilitate Cell and Gene Therapy Forum 2009 to be held in Washington, DC on January 25-28. This forum will assemble global stakeholders from the cellular and gene therapy, biologics, pharmaceutical and device sectors to discuss development and commercialization of cellular and gene therapies
On January 25th, Mr. Faulkner will deliver a plenary lecture entitled A Comparison with the Commercialization Path of Biologics and Targeted Therapies: What lessons Can Cell and Gene Therapy Companies Learn to Avoid Reinventing the Wheel? A description of the session is provided below:
In recent years a new wave of biologics and other emerging technologies have entered the market. Such technologies offer opportunities for increasingly targeted and personalized medicine, but also often come with a higher price tag in global health systems struggling to balance quality and cost of care. Cell and gene therapies are similarly poised to offer advantages versus alternative treatment technologies, including the potential for curing complex diseases, but will enter an environment fraught with significant regulatory, reimbursement and other commercialization challenges. What lessons can cell and gene therapy manufacturers take from forerunner complex technologies to avoid the pitfalls and increase opportunities for successful market uptake and reimbursement? What elements of the overall maturation cycle will be the same, and which ones are truly unique to cell and gene therapy? This presentation will explore lessons learned from existing technology examples in the context of the increasingly tumultuous product development environment.
Eric will also serve in a plenary panel entitled Making Money as a Business and an Industry: How Will Value be Driven? and present a talk entitled Reimbursement Planning for Cellular Therapies: What Do Biotech Executives Need to Know? on January 26th and participate in a panel on commercializing cell therapies sponsored by Progenitor Cell Therapies, LLC.
Mr. Faulkner’s responsibilities at RTI Health Solutions (RTI-HS) involve evaluation of US and international pricing and reimbursement issues, health technology assessment practices, product reimbursement and commercialization strategies and changing health policy. He has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology and the Personalized Health Care Initiative of the US Department of Health and Human Services. He is also serving as a lead editor for an upcoming book entitled Medical Device and Diagnostics Outcomes Research: Issues and Good Research Practices, sponsored by the US Medical Device and Diagnostics Council of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). He is also a Leadership Committee member of the Business Models and Reimbursement Working Group of the International Society for Cellular Therapy (ISCT).
In addition to responsibilities at RTI, Mr. Faulkner also serves as Executive Director of the Genomic Biotech Institute (GBI) of the National Association of Managed Care Physicians (NAMCP) and Editor-in-Chief of the GBI special section of the Journal of Managed Care Medicine, Genomics and Biotechnology. He is also an Assistant Professor at the Institute for Pharmacogenomics and Individualized Therapy at the University of North Carolina at Chapel Hill.
If you would like to speak with Eric regarding this conference or pre-arrange a meeting, please contact him at 919-541-6772 or
send him an email.